Zuyderland Medisch Centrum

Running trials

• Recruiting

  A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

  NCT07665450· Phase 3· Source

• Recruiting

  Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer

  NCT07632079· Phase 2· Source

• Recruiting

  Lab Research Using Mini-tumors to Study Prostate Cancer Treatments

  NCT07004582· Source

• Recruiting

  Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension

  NCT07115953· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Source

• Recruiting

  OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes

  NCT06476119· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  NCT06801834· Phase 3· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Source

• Recruiting

  A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

  NCT06841354· Phase 3· Source

• Recruiting

  OBESE-HFpEF: Towards Preventing Obesity Related HFpEF

  NCT07539766· Source

• Not yet recruiting

  Validating Digital Biomarkers to Detect Disease Activity and Disease Progression in Multiple Sclerosis

  NCT06627465· Source

• Recruiting

  Spinal Cord Monitoring in Multiple Sclerosis

  NCT06827834· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Source

• Active, not recruiting

  Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

  NCT05817942· Source

• Recruiting

  Prediction Models for Complications After CRT in Esophageal Cancer

  NCT06366828· Source

• Active, not recruiting

  Lung Cancer Organoids and Patient Derived Tumor Xenografts

  NCT05092009· Source

• Enrolling by invitation

  Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

  NCT04905693· Phase 3· Source

• Active, not recruiting

  SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

  NCT05198674· Source

• Active, not recruiting

  G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study

  NCT04754087· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

  NCT04586010· Phase 3· Source

• Recruiting

  Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

  NCT03860883· Source

• Active, not recruiting

  Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer

  NCT03764553· Phase 2· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer

  NCT03748641· Phase 3· Source

• Active, not recruiting

  A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT03466411· Phase 2/3· Source

• Active, not recruiting

  Multicentric Randomised Trial for Resectable Gastric Cancer

  NCT02931890· Phase 2· Source

• Recruiting

  Prospective Data Collection Initiative on Colorectal Cancer

  NCT02070146· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and esophageal cancer2 recruiting
• Heart failure2 recruiting
• Multiple sclerosis2 recruiting
• Obesity2 recruiting
• Triple-negative breast cancer2 recruiting
• Chronic kidney disease1 recruiting
• Colorectal cancer1 recruiting
• Crohn's disease1 recruiting
• High blood pressure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lung cancer1 recruiting
• Melanoma1 recruiting
• Multiple myeloma1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease

  NCT06381518· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Source

• Completed

  Multicenter Implementation of E-monitoring in Parkinson's Disease

  NCT05164783· Source

• Completed

  PCT-guided Treatment Regarding Antibiotic Use for Acute COPD Exacerbations

  NCT05854901· Source

• Completed

  EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

  NCT04509674· Phase 3· Source

• Completed

  Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands

  NCT03783429· Phase 4· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· Source

• Completed

  Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

  NCT02807636· Phase 3· Source

• Completed

  Laparoscopic Versus Open Gastrectomy for Gastric Cancer

  NCT02248519· Source

• Completed

  Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

  NCT01909453· Phase 3· Source

• Completed

  A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

  NCT01848561· Source

Trial sites

• Zuyderland Hospital1 trial
• Zuyderland Medical Center2 trials
• Zuyderland Medisch Centrum2 trials
• Zuyderland Medisch Centrum - Sittard-Geleen1 trial
• Zuyderland Medisch Centrum Stichting - Internal Medicine - Hematology0 trials
• 5280063 - Zuyderland Medisch Centrum, Heerlen1 trial
• Zuyderland hospital2 trials
• Zuyderland Medical Center3 trials
• Zuyderland Medisch Centrum8 trials
• Zuyderland Medisch Centrum - Heerlen5 trials
• Zuyderland Medisch Centrum /ID# 1696990 trials
• Zuyderland Medisch Centrum0 trials
• Zuyderland Medical Centre1 trial
• Zuyderland Medisch Centrum1 trial
• Zuyderland Medisch Centrum - Heerlen0 trials
• Zuyderland Medisch Centrum - Sittard-Geleen0 trials
• Zuyderland Medical Centre (Site 4507)1 trial
• Stichting Zuyderland Medisch Centrum2 trials
• Zuyderland Medical Center3 trials
• Zuyderland Medisch Centrum3 trials
• Zuyderland Medisch Centrum /ID# 982411 trial
• Zuyderland Medisch Centrum - Sittard Geleen1 trial

Conditions

Diseases this institution publishes on or runs trials for.

• Ankylosing spondylitis39 works · 0 trials